Gilead Sciences Beats Q4 EPS Forecast

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.Gilead Sciences (GILD 0.69%), a major player in the biotechnology sector, reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 11, that topped analysts' consensus estimates. Adjusted earnings per share of $1.90 came in well ahead of the estimated$1.74. Revenue for the quarter hit $7.57 billion compared to the expected$7.15 billion. A key highlight was the robust performance in t ...